Skip to main content
SpringerLink
Log in

Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. When combined with anthracyclines, the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin™) provides significant clinical benefit for women with HER2-overexpressing metastatic breast cancer. However, its use is limited by severe cardiotoxicity. To clarify whether myocardial HER2 and HER4 expression in response to anthracycline exposure and cardiac damage contributes to cardiotoxicity, we assessed expression of HER2 and HER4 in pathologically altered myocardium.

Experimental design. Cardiac biopsies from 60 patients with severe heart disease and cardiac tissue from 35 patients with breast cancer were obtained. Twenty-five of the patients with breast cancer had previously received anthracyclines. Three of 10 anthracycline-naïve patients with breast cancer had received trastuzumab. Expression of HER2 and HER4 was analyzed immunohistochemically (HER2: HercepTest™/A0485 (Dako), Cy3 detection (Dianova); HER4: Ab-4 (NeoMarkers)). FISH analysis (Ventana) was used to assess HER2 gene amplification.

Results. Immunohistochemistry revealed weak HER2 membrane staining in six cardiac biopsies, appearing as dotted staining of the whole cell membrane and intensified HER2 signal using fluorescent Cy3 labeling. No HER2 membrane staining was detected in the remaining 54 cardiac biopsies or in the myocardium of the 35 patients with breast cancer. HER2 gene amplification was not observed. All specimens showed the mild cytoplasmatic HER4 staining of normal myocardium. No strong HER4 expression was detected.

Conclusions. Cardiac alterations are not associated with an strong increase in HER2 and HER4 levels. IHC detects potential low-level HER2 expression in some samples. However, a more sensitive technique may be needed for studies of the role of HER2 in cardiac tissue. These data do not exclude a role for inhibition of cardiac HER2 expression by trastuzumab in the onset of heart failure in trastuzumab-treated patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26: 78-83, 1999

    Google Scholar 

  2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2638, 1999

    Google Scholar 

  3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002

    Google Scholar 

  4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001

    Google Scholar 

  5. Feldman AM, Lorell BH, Reis SE: Trastuzumab in the treatment of metastatic breast cancer. Anticancer therapy versus cardiotoxicity. Circulation 102: 272-274, 2000

    Google Scholar 

  6. Ewer MS, Gibbs HR, Swafford J, Benjamin RS: Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26: 96-101, 1999

    Google Scholar 

  7. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61: 58-66, 2001

    Google Scholar 

  8. Aikat S, Francis GS: Trastuzumab therapy and the heart: palliation at what cost? Congest Heart Fail 7: 188-190, 2001

    Google Scholar 

  9. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394-398, 1995

    Google Scholar 

  10. Chien KR: Stress pathways and heart failure. Cell 98: 555-558, 1999

    Google Scholar 

  11. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA: Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273: 10261-10269, 1998

    Google Scholar 

  12. Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP: Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 139: 4756-4764, 1998

    Google Scholar 

  13. Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, Marchionni MA, Lorell BH: Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 100: 407-412, 1999

    Google Scholar 

  14. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ: Expression of the c-erbB-4/HER 4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185: 236-245, 1998

    Google Scholar 

  15. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66: 1116-1121, 1992

    Google Scholar 

  16. Marchionni MA: Cell-cell signaling. neu tack on neuregulin. Nature 378: 334-335, 1995

    Google Scholar 

  17. Chien KR: Myocyte survival pathways and cardiomyopathy: implications for trastuzumab toxicity. Semin Oncol 27: 9-14, 2000

    Google Scholar 

  18. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross Jr J, Chien KR, Lee KF: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 8: 459-465, 2002

    Google Scholar 

  19. Qiu Y, Ravi L, Kung HJ: Requirement of ErbB2 for signaling by interleukin-6 in prostate carcinoma cells Nature 393: 83-85, 1998

    Google Scholar 

  20. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross Jr J, Muller W, Chien KR: Loss of gp 130 cardiac muscle cell survival pathway is a critical event in the onset of muscle cell survival during biomechanical stress. Cell 97: 189-198, 1999

    Google Scholar 

  21. Uray IP, Connelly JH, Thomazy V, Shipley GL, Vaughn WK, Frazier OH, Taegtmeyer H, Davies PJ: Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant 21: 771-782, 2002

    Google Scholar 

  22. Schneider JW, Chang AY, Rocco TP: Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 28: 8-26, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology, Charité Campus Virchow Clinic, Berlin, Germany

    Ilka B. Fuchs, Solveig Landt, Anke Kleine-Tebbe & Werner Lichtenegger

  2. Department of Gynecology, Marienhospital Herne, Ruhr University, Bochum, Germany

    Helmut Bueler & Gerhard Schaller

  3. Department of Cardiology, University Hospital Benjamin Franklin, Berlin, Germany

    Uwe Kuehl

  4. Department of Pathology, University Hospital Benjamin Franklin, Berlin, Germany

    Sarah Coupland

Authors
  1. Ilka B. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Solveig Landt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helmut Bueler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Uwe Kuehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sarah Coupland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anke Kleine-Tebbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Werner Lichtenegger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gerhard Schaller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fuchs, I.B., Landt, S., Bueler, H. et al. Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™). Breast Cancer Res Treat 82, 23–28 (2003). https://doi.org/10.1023/B:BREA.0000003916.39959.73

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000003916.39959.73

Search

Navigation